On May 19, Sarepta Therapeutics Inc (NASDAQ:SRPT) announced plans to complete a New Drug Application (NDA) for eteplirsen, Sarepta’s lead product candidate. SRPT …
In a research report released Tuesday, Oppenheimer analyst Christopher Marai maintained an Outperform rating on Cytori Therapeutics Inc (NASDAQ:CYTX) with a $10 price target, following …
In a research report published Wednesday, Oppenheimer analyst Christopher Marai maintained an Outperform rating on Sarepta Therapeutics Inc (NASDAQ:SRPT) with a $45 price target, …
After ImmunoGen, Inc. (NASDAQ:IMGN) announced that Takeda, a Japanese pharmaceutical company, will license their new cancer therapies that use novel antibody drug conjugate (ADC) technology, Oppenheimer …
Christopher Marai of Oppenheimer is optimistic going into the Dystrophin Methodology Workshop on March 20, which will be hosted by the FDA-NIH. Subsequently, the analyst …
In its report published Monday, Oppenheimer analyst Christopher Marai has boosted the price target of Incyte Corporation (NASDAQ:INCY) stock to $89 (from $75), following the company’s …
In a research report released today, Oppenheimer analyst Christopher Marai reiterated an Outperform rating on Celldex Therapeutics (NASDAQ:CLDX) with a $36 price target, …
Oppenheimer analyst Christopher Marai out today with his second note this week on Celldex Therapeutics (NASDAQ:CLDX) maintaining an Outperform rating, with a $36 price target, as …
Oppenheimer analyst Christopher Marai reiterated an Outperform rating on Celldex Therapeutics (NASDAQ:CLDX) with a price target of $36.00, which represents a potential upside …
In a research note published Monday, Oppenheimer analyst Christopher Marai assigned a Perform rating on ImmunoGen (NASDAQ:IMGN), No price target was provided. Marai commented: “ImmunoGen reported …
